Systemic Treatment for Adults with Synovial Sarcoma.
![Thumbnail](/bitstream/handle/internal/3103/11864_2018_Article_525.pdf.jpg?sequence=45&isAllowed=y)
View/ Open
Date
2018-03-07ICR Author
Author
Desar, IME
Fleuren, EDG
van der Graaf, WTA
Type
Journal Article
Metadata
Show full item recordAbstract
Opinion statement Synovial sarcoma (SS) is a rare, yet highly malignant, type of soft tissue sarcoma (STS), for which survival has not improved significantly during the past years. In this review, we focus on systemic treatment in adults. Compared to other STS, SS are relatively chemosensitive. Ifosfamide and ifosfamide combinations are active in different lines of treatment. In high-risk extremity and chest wall STS, neoadjuvant doxorubicin and ifosfamide has shown as much activity as high-dose ifosfamide. There are indications that combination chemotherapy with doxorubicin and ifosfamide in this setting improves outcome. In the first-line metastatic setting, combination treatment with doxorubicin and ifosfamide is a preferred option in fit patients, while in other patients, sequential doxorubicin and ifosfamide can be considered. In second and later lines, pazopanib and trabectedin have shown activity. Many new approaches to treat metastatic SS are currently under investigation, both preclinical as well as clinical, including other receptor tyrosine kinase inhibitors, epigenetic modulators, compounds interfering with DNA damage response (DDR), and immunotherapy.
Collections
Subject
Humans
Sarcoma, Synovial
Sulfonamides
Ifosfamide
Pyrimidines
Doxorubicin
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Adult
Trabectedin
Research team
Clinical and Translational Sarcoma
Language
eng
License start date
2018-03-07
Citation
Current treatment options in oncology, 2018, 19 (2), pp. 13 - ?